( Frankfurt:PMR, LSE:0RC6, OTC-PINK:PHMMF, Bloomberg:1339327D@MM, Bloomberg:PHM@SM, Bloomberg:PHMMF@US, Bloomberg:PMR@GR, RICS:0RC6.L, RICS:PHM, RICS:PHMMF, RICS:PHMR, RICS:PHMREUR, RICS:PHMRSS, RICS:PMR, RICS:PMR.F, RICS:PMRG, RICS:PMRG.F, ISIN:ES0169501030, Berlin:PMR, Madrid:PHM, Mexico:1339327D, OTC-BB:PHMMF, OtherOTC:PHMMF, SpanishCats:PHM, SpanishCats:PHMRSS, Stuttgart:PMR, XETRA:PMR )

News from PharmaMar A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 12, 2017, 10:28 ET Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple

- Plitidepsin showed the capability to cancel out the activity of the osteoclasts -cells responsible for the destruction of bone- at a...


Dec 11, 2017, 08:30 ET PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting

- As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus...


Nov 15, 2017, 08:30 ET Phase III Trial With Zepsyre® in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC

PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that...


Nov 14, 2017, 08:30 ET PharmaMar to Present at the Stifel 2017 Healthcare Conference

PharmaMar (MCE: PHM) will present and meet institutional investors in on one meetings at the Stifel Nicolaus Weisel Healthcare Conference on...


Nov 14, 2017, 02:30 ET GENOMICA recibe la autorización de comercialización de sus kits de diagnóstico y equipos en Corea del Sur

GENOMICA, compañía del grupo PharmaMar, la compañía líder en diagnóstico molecular y perteneciente al Grupo PharmaMar (MCE:PHM), ha anunciado que...


Nov 14, 2017, 01:30 ET GENOMICA obtient une autorisation pour la commercialisation de ses kits et instruments de diagnostic en Corée du Sud

GENOMICA, une société de diagnostic moléculaire de premier plan du groupe PharmaMar (MCE : PHM), a annoncé avoir reçu l'autorisation des...


Nov 14, 2017, 01:30 ET GENOMICA erhält Zulassung zur Vermarktung seiner Diagnosekits und Instrumente in Südkorea

GENOMICA, ein führendes Molekulardiagnostik-Unternehmen der PharmaMar-Gruppe (MCE: PHM) hat bekannt gegeben, dass es die Zulassung zur...


Nov 13, 2017, 08:30 ET PharmaMar Presents Positive Results from a Phase II Study of lurbinectedin in Ewing's Sarcoma at the CTOS International Congress

PharmaMar (MCE: PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing's sarcoma at the Connective Tissue Oncology...


Nov 07, 2017, 08:30 ET PharmaMar and Boryung Pharm Sign A Licensing Agreement for Zepsyre® (lurbinectedin) in Korea

PharmaMar (MCE: PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre®...


Nov 04, 2017, 08:30 ET PharmaMar Announces Partnership with 8th National Race to End Women's Cancer in Support of "End Women´s Cancer Weekend" in Washington D.C.

• According to the Foundation for Women´s Cancer, every five minutes a woman will receive a gynecologic cancer diagnosis of cervical, ovarian,...


Oct 19, 2017, 08:30 ET The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001

Sylentis, a Pharmaceutical Company of PharmaMar Group (MCE: PHM), pioneer in the development of new compounds based on genetic silencing...


Oct 18, 2017, 08:30 ET Final Data on Phase I/II in Small-cell Lung Cancer with Zepsyre® Presented at the IASCLC 18th World Conference on Lung Cancer in Japan

PharmaMar (MCE: PHM), a biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs, has presented...


Oct 10, 2017, 08:30 ET PharmaMar Will Present Final Data on PM1183 During the 18th World Lung Conference in Japan

PharmaMar (MCE: PHM) will present the final efficacy and safety data obtained from the Phase I/II trial combining PM1183 (lurbinectedin) with...


Oct 05, 2017, 04:35 ET PharmaMar soumet une demande d'autorisation de mise sur le marché d'Aplidin® en Suisse

- À la fin de l'année 2016, Pharma Mar S.A. avait sollicité l'autorisation de commercialiser le produit dans l'Union européenne -...


Oct 05, 2017, 02:30 ET PharmaMar reicht Marktzulassungsgesuch für Aplidin® in der Schweiz ein

- Pharma Mar S.A. reichte das Marktzulassungsgesuch in der Europäischen Union Ende 2016 ein - Das behördliche Verfahren für...


Oct 04, 2017, 08:30 ET PharmaMar Submits the Marketing Authorisation Application for Aplidin® in Switzerland

- Pharma Mar S.A. submitted the Marketing Authorisation Application in the European Union at the end of 2016 - The regulatory...


Sep 25, 2017, 08:30 ET PharmaMar: Sylentis Presents New Data on a New Eye Drop siRNA for the Treatment of Retinal Diseases Avoiding Intraocular Injections

- This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is...


Sep 25, 2017, 02:30 ET PharmaMar : Sylentis présente de nouvelles données sur un nouveau pARNi à usage topique pour le traitement des maladies de la rétine évitant les injections intraoculaires

- Ce nouveau traitement expérimental, basé sur l'interférence ARN, atteint la rétine lorsqu'il est administré sous forme de gouttes...


Sep 20, 2017, 08:30 ET PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors

With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (MCE:PHM) announces the start...


Sep 20, 2017, 06:04 ET PharmaMar débute des études cliniques avec un nouveau composé, PM14, chez des patients atteints de tumeurs solides

Désireux de trouver une solution aux besoins insatisfaits des patients souffrant de différents types de cancer, PharmaMar (MCE: PHM) annonce le...


Sep 20, 2017, 05:45 ET PharmaMar fa partire uno studio clinico con nuovo composto -PM14- nei pazienti con tumori solidi

Con l'obiettivo di trovare una soluzione alle esigenze senza risposta dei pazienti affetti da diversi tipi di cancro, PharmaMar (MCE: PHM)...


Sep 20, 2017, 05:42 ET PharmaMar startet klinische Studien mit einem neuen Präparat -PM14- bei Patienten mit soliden Tumoren

Mit der Motivation, eine Lösung für den unerfüllten Bedarf von Patienten mit unterschiedlichen Arten von Krebs zu finden, kündigt PharmaMar (MCE:...


Sep 14, 2017, 08:36 ET Neue positive Daten zeigen Ansprechrate von 36 % auf PM1183-Monotherapie bei Patienten mit fortgeschrittenem oder rückfälligem kleinzelligem Lungenkarzinom

PharmaMar (MCE: PHM) präsentierte auf dem Kongress der europäischen Gesellschaft für medizinische Onkologie (ESMO) in Madrid positive Ergebnisse...


Sep 12, 2017, 16:19 ET Neue positive Daten zeigen Ansprechrate von 36 % auf PM1183-Monotherapie bei Patienten mit fortgeschrittenem oder rückfälligem kleinzelligem Lungenkarzinom

PharmaMar (MCE: PHM) präsentierte auf dem Kongress der europäischen Gesellschaft für medizinische Onkologie (ESMO) in Madrid positive Ergebnisse...


Sep 12, 2017, 13:30 ET New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer

PharmaMar (MSE: PHM) presented during the European Society for Medical Oncology congress (ESMO), held in Madrid, positive results of PM1183...